CMB International Securities analyst Jill Wu has maintained their bullish stance on TRSBF stock, giving a Buy rating on September 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jill Wu has given her Buy rating due to a combination of factors that highlight 3SBio’s promising future prospects. The company has reported a significant increase in net profit, primarily driven by a substantial reduction in finance costs, despite a slight dip in revenue. This financial improvement is complemented by the anticipated launch of several new drugs in the coming years, which are expected to bolster product sales and offset the pressure on legacy products.
Furthermore, the potential of 707 (PD-1/VEGF) to become a global blockbuster is a key factor in the positive outlook. Pfizer’s involvement in advancing 707’s global clinical development, including potential Phase 3 trials and combination regimens, is seen as a catalyst for 3SBio’s earnings growth. Additionally, the company’s innovative pipeline, including drugs like 705 and 706, entering global development stages, reinforces its strategy for global innovation. The sustained growth of the alopecia franchise, despite challenges faced by TPIAO, further supports the Buy rating.
In another report released on September 2, CLSA also maintained a Buy rating on the stock with a HK$37.10 price target.